One of the most common questions people ask after starting buprenorphine, methadone, or naltrexone is when they can stop. Sometimes the question comes from a family member. Sometimes it comes from an employer, a friend, or the person's own sense that needing a daily medication means they are not really recovered.

This article explains what federal guidance and recent research say about how long medication for opioid use disorder should continue, and how a decision to stop is supposed to be made.

Start with what the medications do

NIDA describes opioid use disorder as a chronic, treatable medical condition. FDA-approved medications, including methadone, buprenorphine, and naltrexone, can help people stop or reduce opioid use. They can ease withdrawal and reduce cravings without creating the strongly pleasurable effects of opioid drugs (NIDA).

NIDA also notes that these medications reduce the risk of overdose death and of behaviors that spread infections such as HIV and hepatitis C. Even so, fewer than 1 in 5 people with opioid use disorder receive them (NIDA).

That is the starting point for the duration question. The medication is treating a medical condition. It is not a phase to finish as fast as possible.

There is no standard end date

SAMHSA's Treatment Improvement Protocol 63 is the federal reference guide on these medications. It says there is no one-size-fits-all approach. Many people benefit from medication for varying lengths of time, including lifelong treatment (TIP 63).

The guide is direct on one point: arbitrary time limits on the duration of medication treatment are inadvisable (TIP 63). A rule like "six months and then you taper" is not based on the evidence.

TIP 63 describes the best results as occurring when a person receives medication for as long as it provides a benefit. This is often called maintenance treatment. Maintenance gives people time to make the life changes linked with long-term recovery, such as changing the people, places, and things connected with use. It also reduces cravings and withdrawal, and helps people manage parenting, school, or work (TIP 63).

Why stopping is harder than it looks

People sometimes assume that if they taper slowly enough, they can avoid problems. TIP 63 explains why that is often not the case. Patients who discontinue medication generally return to illicit opioid use, even when stopping is slow and careful. The more severe form of opioid use disorder is more than physical dependence. It changes the brain's reward circuitry, which affects thinking, emotions, and behavior (TIP 63).

The guide summarizes several studies. Most patients who try to stop methadone return to use during or after the taper. In one large population-based study, only 13 percent of patients who tapered from methadone had successful outcomes, defined as no treatment reentry, death, or opioid-related hospitalization within 18 months (TIP 63).

What the research says about timing

Two studies of U.S. veterans help explain the stakes.

The first followed veterans who received buprenorphine between 2008 and 2017. On any given day, those not receiving buprenorphine were about 4.3 times more likely to die by suicide or overdose than those receiving it. The risk was highest in the 8 to 14 days after treatment was stopped (Vakkalanka et al.).

The second looked at more than 32,000 veterans who started buprenorphine, methadone, or extended-release naltrexone. It asked how the benefit for survival changed with each additional year on medication. Compared with six months of treatment, gains continued through about four to five years. The authors concluded that the survival benefit continues through at least four years, and that quality measures built around six months of treatment may not be enough (Hayes et al.).

Both studies are observational. They show strong associations, not proof of what will happen to one person. But they point the same direction as the federal guidance: stopping early carries real risk.

If you want to stop, how it should happen

Wanting to come off medication is not wrong, and it is a reasonable topic to raise. TIP 63 says decisions about stopping should be based on the evidence, an individualized assessment, and a treatment plan that the patient and prescriber develop and agree on together (TIP 63).

The same guide lists what should come with a taper (TIP 63):

  • Counseling and recovery support services offered during the process.
  • Monitoring during and after the dose taper.
  • An offer of extended-release naltrexone.
  • Encouragement to restart medication quickly if opioid use returns.

Medication also should not be the whole plan. TIP 63 says people with opioid use disorder should have access to mental health services, medical care, addiction counseling, and recovery support alongside medication (TIP 63).

Questions worth asking your prescriber

  • What would tell us that medication is still helping me?
  • If I want to taper someday, what would need to be in place first?
  • How would we watch for warning signs during and after a taper?
  • What is the plan if I return to use after stopping?
  • Should I have naloxone at home during any dose change?

The short version

There is no set end date for medication for opioid use disorder. Federal guidance calls fixed time limits inadvisable and describes the best results when medication continues as long as it helps. Research on veterans links stopping with higher risk of death, especially in the first two weeks, and finds survival benefits continuing for years. If you want to stop, that conversation belongs with your prescriber, with a plan, support, and a fast path back to medication if needed.